Francesca Gaia Bosisio1,2,3†
Desirè Mingardi1,2,3†
Elisabetta Moretti1,2,3†
Giorgia Muzi1,2,3†
Francesco Russomanno1,3†
Nicola Tassani1,2,3†
Deborah Stassaldi1
Claudia Agabiti Rosei1,3
Carolina De Ciuceis1,3
Massimo Salvetti2,3
Maria Lorenza Muiesan1,3*- 1UOC 2 Medicina, ASST Spedali Civili di Brescia, Brescia, Italy
- 2Emergency Medicine ASST Spedali Civili Brescia, Brescia, Italy
- 3Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
Malignant hypertension (MH) is characterized by severe hypertension (usually grade 3) associated with fundoscopic changes (flame hemorrhages and/or papilledema), microangiopathy and disseminated intravascular coagulation. In addition encephalopathy, acute heart failure and acute deterioration in renal function may be present. The term “malignant” reflects the very poor prognosis for this condition if untreated. When severe hypertension is associated with hypertension-mediated organ damage (HMOD) a life-threatening situation that requires immediate but careful intervention occurs (hypertensive emergency). In the last few years an increase in the number of patients with malignant hypertension has been observed, especially among those patients with black ethnicity. Limited access to treatment and the poor adherence to anti-hypertensive therapy may contribute to the development of hypertensive emergencies. It is considered appropriate to study patients in order to rule out thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. In fact, the microvascular damage caused by malignant hypertension can favor intravascular hemolysis like Thrombotic Microangiopathies (TMs). TMs may present in three different clinical conditions: typical hemolytic uremic syndrome (HUS), atypical hemolytic uremic syndrome (aHUS) and thrombotic thrombocytopenic purpura (TTP). TMs can arise in the context of other pathological processes, including malignant hypertension.
Introduction
A 46-years old man, smoker, without previous diseases in his past medical history, not taking any medications at the time of hospitalization and with a family history of diabetes and hypertension, was admitted to the Emergency Department (ED) of a spoke hospital. At admission he was complaining chest pain, headache and vomiting starting a few days before admission. At ED admission vital parameters were as follows: heart rate (HR) 81 bpm, blood pressure (BP) 176/101 mmHg, peripheral arterial oxygen saturation (SpO2) 99% with O2 therapy (3 L/min) and a Glasgow Coma Scale (GCS) value of 15 without other significant clinical or neurological findings. Laboratory investigations showed mild reduction of hemoglobin value (10 g/dL) with normal mean corpuscular volume (91.6 fL), thrombocytopenia (50,000/dL), severe increase of creatinine (6.52 g/dL), mild hypokalemia (2.9 mEq/L), normal sodium value (138 mEq/L), and severe increase of Troponin-T (215 ng/L). The ECG showed ST-elevation in precordial leads V1-V2, Sokolow–Lyon index 46 mm, left ventricular hypertrophy (LVH), and strain pattern (down sloping convex ST segment with an inverted asymmetrical T-wave opposite to the QRS axis) (Figure 1A). Chest X-ray showed cardiomegaly (Cardio-Thoracic index 0.61) and brain computerized tomography did not highlight any significant findings.
Figure 1. (A) ECG at Emergency Department (ED) admission. (B) ECG a few days after hospitalization.
Case description
Based on the clinical suspicion of acute coronary syndrome, the patient was transferred to the Intensive Care Unit (ICU) of the hub hospital ASST Spedali Civili in Brescia. A transthoracic echocardiogram confirmed increased thickness of left ventricular (LV) walls [interventricular septum (IVS) 21 mm, posterior wall (PW) 20 mm], “super” normal left ventricular ejection fraction (LVEF) 70%, wall motion abnormalities (basal and middle antero-lateral segments akinesia and posterior basal portion hypokinesia) and suspect of infiltrative pathology. Coronary angiography was performed, showing moderate coronary artery disease, i.e., 40% stenosis of the anterior interventricular artery, 50% stenosis of the third branch of the left marginal artery and coronary sclerosis of the posterolateral branch of the circumflex artery and of the third marginal branch of the right posterolateral artery (Figure 2).
Figure 2. Coronary angiography: sequence of different frames.
Based on the coronary angiography results, other invasive treatment was excluded. Chest pain disappeared after nitrate i.v. administration.
In order to reduce BP, intravenous nitroprusside first and nitrate thereafter were given, with a sudden decrease of systolic and diastolic BP values (from 200/100 to 130/80 mmHg). Concomitantly negative hyperacute T waves in the anterior leads were observed at ECG, suggesting myocardial injury, worsened by the rapid fall in BP (Figure 1B).
The patient was transferred to the high intensity ward of the Internal Medicine Department for further diagnostic and therapeutic management.
Laboratory findings showed low platelet count (nadir 50,000/dL), anemia with high lactate dehydrogenase (LDH), reduced haptoglobin and schistocytes at the peripheral blood smear, all suggesting thrombotic microangiopathy (TMA), in the presence of severe hypertension and multiple organ damage (acute kidney injury and myocardial damage). Complement dysregulation, based on C5b-9 or membrane attack complex (MAC) of 475 ng/ml (normal values between 140 and 280 ng/ml) was detected. Plasma renin and aldosterone were measured in addition to urinary metanephrines and aldosterone and renin were elevated (aldosterone 44,5 ng/dL, renin 81,8 uUI/mL). Cortisol and thyroid stimulating hormone (TSH) were in physiological range.
A renal arteries ultrasound was performed in the suspicion of renovascular hypertension; no renal arteries stenosis was observed, although resistance indices were increased in the right interlobar arteries.
In order to rule out a possible auto-immune diseases, antinuclear antibodies (ANA), extractable nuclear antigen antibodies (ENA), anti-neutrophil cytoplasmic antibodies (ANCA), anti-dsDNA and anticardiolipin antibodies have been also dosed, and the Coombs test has been performed.
A brain magnetic resonance (MRI) ruled out posterior reversible encephalopathy syndrome (PRES), but showed the presence of small areas of aspecific gliosis in the white fronto-temporal lobes.
The funduscopic examination showed a large number of retinal flame hemorrhages located at peripapillar level. Retinal fluoroangiography and optical coherence tomography (OCT) ruled out ischemic areas, but additionally identified hard intra-retinal exudates with papilledema (Figure 3).
Figure 3. Optical coherence tomography (OCT) showing hard intra-retinal exudates with papilledema.
During the first 2 days of hospitalization, intravenous infusion of nitroglycerin and labetalol were maintained with a target systolic BP values between 150 and 160 mmHg. Thereafter intravenous therapy was replaced by transdermal nitroglycerin, and oral administration of amlodipine and carvedilol, with a progressive association with doxazosin.
A low dose of angiotensin-converting enzyme inhibitor (ACEi) (ramipril) was associated, despite the persistence of high creatinine values. Before discharge furosemide, atorvastatin, acetylsalicylic acid, a proton pump inhibitor, sodium bicarbonate and calcifediol were added to antihypertensive therapy.
The patient was discharged after a 40 days hospitalization [because of a concomitant paucisymptomatic Severe Acute Respiratory Syndrome–CoronaVirus2 (SARS-CoV-2) infection].
Genetic testing had been performed during the ICU hospitalization and nephrologist consultation in order to exclude atypical hemolytic uremic syndrome and Fabry disease (because of the suspicion of infiltrative hypertrophic cardiomyopathy).
After 120 days of follow-up, blood tests showed normal platelet count and hemoglobin level, but still increased creatinine (4.7 mg/dl).
Office BP values were high (180/115 mmHg) and the patient confirmed poor adherence to drug therapy. The importance of a regular treatment administration was reinforced to the patient and a 24 ABPM was performed, showing BP values still elevated but closer to target values, with dipping pattern.
ECG showed reduction of the Sokolow–Lyon index (26 mm) and persistence of negative T waves (Figure 4).
Figure 4. ECG at follow-up visit 4 months after discharge.
An echocardiogram (performed 4 months after the admission) showed absence of wall motion abnormalities, normal LVEF (65%) and significant reduction of LVH (LV mass index 67.8 g/m2.7, IVS and PW thicknesses 14.1 and 16.7 mm, respectively), left atrial dilatation and slight increase of ascending aorta diameter (Figures 5A,B).
Figure 5. (A) Echocardiography after 2 months since the admission. (B) Echocardiography after 4 months since the admission.
After 4 months from hospitalization a renal biopsy was performed showing findings suggestive of parenchymal renal damage and global glomerulosclerosis, possibly secondary to arterial hypertension. The renal biopsy excluded mesangial IgA deposits.
The patient is regularly seen in the outpatient clinic and will undergo a follow-up ECG and echocardiogram in the next months.
Discussion
We report the case of a patient with malignant hypertension (MH). Several features suggest the diagnosis, including severe renal and cardiac damage, thrombotic microangiopathy and grade III-IV retinal fundus changes.
The patient clinical presentation was typical of a type 2 acute myocardial infarction (ST elevation in V1 and V2 associated with high troponin levels, wall motion changes and severe chest pain) due to moderate coronary angiography and increased oxygen demand and uptake (anemia and acute rise in BP). MH was initially underestimated and the diagnostic and therapeutic approach was first focused on the acute coronary syndrome hypothesis.
However, MH is not quite an obsolete diagnosis yet and the principles of early diagnosis, detailed systematic evaluation and effective treatment remain key factors for a longer event free survival.
After coronary angiography, specific tests were obtained to assess the cardiac, renal, and vascular damage, in addition to the exclusion of secondary forms of hypertension. ECG findings were typical of LVH secondary to hypertension, including both voltage and repolarization abnormalities such as the strain pattern. The hypothesis of Fabry’s disease proposed by the specialists who performed the first echocardiogram appears to be unlikely due to echocardiographic reduction of LV walls thickness at follow-up, obtained during an improvement in BP control.
More importantly we performed a retinal fundus examination that confirmed the presence of flame hemorrhages and a grade 3 Keith Wegener retinopathy, while papilledema was described at retinal fluoroangiography and optical coherence tomography. Unfortunately retinal fundus is still poorly prescribed in patients with acute BP elevation, despite new technical progresses that could widen its use (1, 2).
As suggested by guidelines (3, 4), the appropriate treatment involves early intravenous infusion of antihypertensive agents, although the decrease of BP should be particularly cautious and progressive. A decrease of mean blood pressure (MBP) of about 25% is suggested, to be reached in several hours.
In fact, the reduction in BP obtained in the ICU by nitroprussiate and nitroglycerin infusion induced a progression of myocardial damage, due to the reduction in coronary perfusion pressure, as described several years ago (5). In this patient the presence of LVH and of concomitant moderate atherosclerosis of large coronary arteries have further worsened myocardial damage.
A more permissive blood pressure target (160/95 mmHg) was achieved by reducing intravenous antihypertensive drugs, and a subsequent titration of oral treatment, allowing a more cautious and progressive reduction of blood pressure values.
There are no formal guidelines on the treatment of MH, due to the absence of randomized controlled clinical trials. The current consensus for treatment involves early intravenous infusion of antihypertensive agents, with a cautious and progressive decrease of BP. Labetalol, nicardipine, sodium nitroprusside and urapidil are the most often used and all appear to be safe and effective for the treatment of malignant hypertension (3). Whether intravenous therapy is always necessary is a matter of debate given recent reports that oral medication can also result in the controlled reduction of BP (6, 7). Oral therapy, in particular blockers of the renin–angiotensin system, may improve the management of MH. It offers a suitable treatment option in low-income countries where the condition remains relatively prevalent and in “uncomplicated” MH, oral treatments could be used to gradually lower BP to normal ranges over several days (6–10) (Table 1).
Table 1. Malignant hypertension therapy.
In this patient white matter lesions were observed in the frontotemporal lobes. Rubin et al. (8), following systematic evaluation of the brain by MRI, have observed that the white matter lesions were more prevalent in the posterior regions, with 51% of included patients affected. However, in 27% of the Bordeaux cohort other locations of white matter lesions were found.
This patient presented with renal damage and hypokalemia and in practice, these two findings with high BP should indicate malignant hypertension or TMA. Patients with malignant hypertension usually show hyperaldosteronism secondary to renin activation (8, 9), and the kidneys continue to excrete potassium.
A TMA was diagnosed and a genetic testing is ongoing to rule out the diagnosis of atypical hemolytic uremic syndrome.
The thrombotic microangiopathy can be caused by hemolytic uremic syndrome typical (HUS) and atypical (aHUS) or by thrombotic thrombocytopenic purpura (TTP or Moschcowitz disease) (10–12).
Thrombotic thrombocytopenic purpura was ruled out by the ADAMTS-13 assay (negative for mutations and the gene showed a physiological activity). The lack of clinical and anamnestic evidence for infection caused by Shiga toxin-producing E. Coli allowed to rule out the hemolytic uremic syndrome.
Other causes inducing TMA other than malignant arterial hypertension could be excluded (autoimmune diseases, exposure to trigger drugs, solid/hematopoietic organ transplantation, mesangial IgA deposits nephropathy, neoplasms, pregnancy/postpartum period). The atypical hemolytic uremic syndrome will be definitively excluded by the ongoing NGS genetic tests.
We followed the most recent recommendations for patients with MH (3, 4, 7–9). In the acute phase sodium nitroprusside, labetalol, nicardipine, and urapidil all appear to be safe and effective for the treatment of malignant hypertension; we did not use nicardipine because is not easily available in our country and we did not use diuretic therapy because of hypokalemia and pressure natriuresis. The choice of ACE inhibitor, despite the presence of severe increase in creatinine is suggested by some experts but should be started at a very low dose to prevent a sudden decrease in BP and then should be adjusted according to the patient’s response and the renal function (6). Patients with MH present with hypovolemia because of pressure natriuresis, and in some circumstances intravenous saline infusion can be used to correct precipitous BP reduction.
Patient perspective
In patients with MH it is mandatory to prevent other clinical events, to carefully monitor blood pressure values and to avoid large and sudden decrease of BP in order to prevent further organ damage.
In this specific case, it was established to maintain a BP target above 140/85 mmHg to preserve renal and perhaps cardiac perfusion. Renal, cardiac and vascular organ damage should be checked by routine blood tests (including electrolytes and urinary proteinuria monitoring) in order to exclude possible complications of chronic kidney disease, ECG and echocardiogram and retinal fundus.
Adherence to antihypertensive therapy is crucial, as well as avoidance of non-steroidal anti-inflammatory drugs (NSAIDs) and of smoke.
In conclusion, the biggest challenge is to maintain the adherence to treatment and to the follow-up evaluation (13–16).
Data availability statement
The original contributions presented in this study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.
Ethics statement
Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual for the publication of any potentially identifiable images or data included in this article.
Author contributions
DM, FR, DS, CA, CD, MS, and MLM: clinical case management. FB, DM, EM, GM, FR, and NT: clinical data collection. MLM: manuscript revision and chief of the department. All authors contributed to the article and approved the submitted version.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Saladini F, Mancusi C, Bertacchini F, Spannella F, Maloberti A, Giavarini A, et al. Diagnosis and treatment of hypertensive emergencies and urgencies among Italian emergency and intensive care departments. Results from an Italian survey: progetto GEAR (gestione dell’emergenza e urgenza in area critica). Eur J Intern Med. (2020) 71:50–6. doi: 10.1016/j.ejim.2019.10.004
2. Muiesan M, Salvetti M, Paini A, Riviera M, Pintossi C, Bertacchini F, et al. Ocular fundus photography with a smartphone device in acute hypertension. J Hypertens. (2017) 35:1660–5. doi: 10.1097/HJH.0000000000001354
3. Van den Born B, Lip G, Brguljan-Hitij J, Cremer A, Segura J, Morales E, et al. ESC council on hypertension position document on the management of hypertensive emergencies. Eur Heart J Cardiovasc Pharmacother. (2019) 5:37–46. doi: 10.1093/ehjcvp/pvy032
4. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. (2018) 33:3021–104. doi: 10.1093/eurheartj/ehy339
5. Pepi M, Alimento M, Maltagliati A, Guazzi M. Cardiac hypertrophy in hypertension. Repolarization abnormalities elicited by rapid lowering of pressure. Hypertension. (1988) 11:84–91. doi: 10.1161/01.hyp.11.1.84
6. Gosse P, Boulestreau R, Brockers C, Puel C, Rubin S, Cremer A. The pharmacological management of malignant hypertension. J Hypertens. (2020) 38:2325–30. doi: 10.1097/HJH.0000000000002547
7. Boulestreau R, van den Born B, Lip G, Gupta A. Malignant hypertension: current perspectives and challenges. J Am Heart Assoc. (2022) 11:e023397. doi: 10.1161/JAHA.121.023397
8. Cremer A, Amraoui F, Lip G, Morales E, Rubin S, Segura J, et al. From malignant hypertension to hypertension-MOD: a modern definition for an old but still dangerous emergency. J Hum Hypertens. (2016) 30:463–6. doi: 10.1038/jhh.2015.112
9. Van den Born B, Koopmans R, van Montfrans G. The renin-angiotensin system in malignant hypertension revisited: plasma renin activity, microangiopathic hemolysis, and renal failure in malignant hypertension. Am J Hypertens. (2007) 20:900–6. doi: 10.1016/j.amjhyper.2007.02.018
10. Paini, A, Aggiusti C, Bertacchini F, Agabiti Rosei C, Maruelli G, Arnoldi C, et al. Definitions and epidemiological aspects of hypertensive urgencies and emergencies. High Blood Press Cardiovasc Prev. (2018) 25:241–4. doi: 10.1007/s40292-018-0263-2
11. Michael M, Bagga A, Sartain S, Smith R. Haemolytic uraemic syndrome. Lancet. (2022) 400:1722–40. doi: 10.1016/S0140-6736(22)01202-8
12. Domek M, Gumprech J, Lip G, Shantsila A. Malignant hypertension: does this still exist? J Hum Hypertens. (2020) 34:1–4. doi: 10.1038/s41371-019-0267-y
13. Polgreen L, Suneja M, Tang F, Carter B, Polgreen P. Increasing trend in admissions for malignant hypertension and hypertensive encephalopathy in the United States. Hypertension. (2015) 65:1002–7. doi: 10.1161/HYPERTENSIONAHA.115.05241
14. Lip G, Beevers M, Beevers G. The failure of malignant hypertension to decline: a survey of 24 years’ experience in a multiracial population in England. J Hypertens. (1994) 12:1297–305.
15. Van den Born B, Koopmans R, Groeneveld J, van Montfrans G. Ethnic disparities in the incidence, presentation and complications of malignant hypertension. J Hypertens. (2006) 24:2299–304. doi: 10.1097/01.hjh.0000249710.21146.38
Keywords: malignant hypertension, hypertensive emergency, organ damage, atypical hemolytic uremic syndrome, thrombotic microangiopathies, left ventricular hypertrophy, case report
Citation: Bosisio FG, Mingardi D, Moretti E, Muzi G, Russomanno F, Tassani N, Stassaldi D, Agabiti Rosei C, De Ciuceis C, Salvetti M and Muiesan ML (2023) Case report: Area of focus in a case of malignant hypertension. Front. Cardiovasc. Med. 9:1108666. doi: 10.3389/fcvm.2022.1108666
Received: 26 November 2022; Accepted: 16 December 2022;
Published: 13 January 2023.
Edited by:
Guido Iaccarino, University of Naples Federico II, ItalyReviewed by:
Giuliano Tocci, Sapienza University of Rome, ItalyValeria Visco, University of Salerno, Italy
Copyright © 2023 Bosisio, Mingardi, Moretti, Muzi, Russomanno, Tassani, Stassaldi, Agabiti Rosei, De Ciuceis, Salvetti and Muiesan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Maria Lorenza Muiesan, 
marialorenza.muiesan@unibs.it
†These authors have contributed equally to this work